

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet 2 of

<b>Application Number</b>	unassigned
<b>Filing Date</b>	
<b>First Named Inventor</b>	<b>Albert M. FLEISCHNER</b>
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	Nutrimerica

[illegible][illegible]

Date	
Considered	

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	unassigned
		Filing Date	Sept. 2003
		First Named Inventor	Albert M. FLEISCHNER
		Group Art Unit	
		Examiner Name	
Sheet 1	of	Attorney Docket Number	Nutrimerica

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Blum Ph.D. J, Marshall M.D. P. Randomized Clinical Trial for Healthy Weight-Management A Prospective, Randomized, Double-Blind Study to Test the Efficacy of Trimspa. 2001 August: Bangor, Maine, USA.	
		Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et. al. Herbal ephedra /caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord. 2002 May; 26(5): 593-604.	
		Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord. 1992 Apr; 16(4): 269-277.	
		Boozer CN et al., An herbal supplement containing MaHuang-Guarana for weight loss. Obesity Research Center, St. Luke's-Roosevelt Hospital Center and Department of Medicine, Columbia University College of Physicians and Surgeons, New York, 10025, USA.	
		Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord. 1993 Feb; 17Suppl 1:S41-43.	
		Breum L, et al., Comparison of an ephedrine/caffeine combination and dexfluramine in the treatment of obesity. Int J Obes Relat Metab Disord. 1994 Feb; 18(2): 99-103.	
		A Prospective, Randomized, Double-Blind Study to Evaluate the Effect of Lean System 7 on Body Composition. <a href="http://www.humaneticscorp.com/7keto/7ketoabstracts.html#7ketoabstract16">http://www.humaneticscorp.com/7keto/7ketoabstracts.html#7ketoabstract16</a> (Accessed June 26, 2003).	
		Telegraph News: Bushmen to aid slimmers. Available at: <a href="http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2001/09/23/wcact23.xml">http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2001/09/23/wcact23.xml</a> (Accessed April 15, 2003).	
		Business Day: San to benefit from medicinal plant. Available at: <a href="http://www.bday.co.za/bday/content/direct/1,3523,1312966-6099-0,00.html">http://www.bday.co.za/bday/content/direct/1,3523,1312966-6099-0,00.html</a> (Accessed April 15, 2003)	
		Tulp OL, Harbi NA, DerMarderosian A. Mineral Content of Edible Hoodia Plant species. FASEB Vo. 15; No. 4. Abstracts 2.1-537.42. March 7, 2001.	
		Guardian Unlimited Special Reports: It's green, prickly and sour, but this plant could cure obesity and save an ancient way of life. Available at: <a href="http://www.guardian.co.uk/medicine/story/0,11381,868516,00.html">http://www.guardian.co.uk/medicine/story/0,11381,868516,00.html</a> (Accessed April 15, 2003)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	unassigned
		Filing Date	Oct. 2003
		First Named Inventor	Albert M. FLEISCHNER
		Group Art Unit	
		Examiner Name	
Sheet 1	of	Attorney Docket Number	Nutrimerica

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Anon., "Kalahari cactus boosts UK drug firm," (30 July 2002) (BBC Business News, publ.)	
		Dispatch Online: Fat-buster plant could earn millions for SA. Available at: <a href="http://www.dispatch.co.za/2002/05/03/features/FARM3.HTM">http://www.dispatch.co.za/2002/05/03/features/FARM3.HTM</a> (Accessed April 15, 2003)	
		TULP, OL et al, Effect of Hoodia Plant on Food Intake and Body Weight in Lean and Obese LA/Ntul//cp Rats, 15 FASEB Abstracts 338.5 (7 March 2001 ?) (abstract only)	
		BANDO, Hideo et al., "Constituents of Asclepiadaceae Plants: Component of Stapelia grandiflora Mass," 22 Chem. Pharm. Bull. 1209 (1974)	
		YOSHII, Ehchi et al., "Preng-14-en-ones: Facile Preparation...", 20 Chem. Pharm. Bull. 1827 (1972)	
		CHEN, Jijun et al., "A Novel C21 Steroidal Glycoside From Marsdenia Incisa," 115 Plant Biochem. 591, 115:275751j (1991) (abstract only)	
		DOLLE, R.E. et al., "Total Synthesis of Elfamycins: Aurodox and Efrotomycin...", 107 J.Am. Chem. Soc. 1691 (1985)	
		DOLLE, R.E. et al., "Total Synthesis of Elfamycins: Aurodox and Efrotomycin #2...", 107 J.Am. Chem. Soc. 1695 (1985)	
		DOUKETIS, James D. et al., "Periodic Health Examination, 1999 Update: 1. Detection, Prevention and Treatment of Obesity," 160 Can. Med. Assoc. Journ. 513 (1999)	
		FAN, Wei et al., "Role of Melanocortinergic Neurons in Feeding and the Agouti Obesity Syndrome," 385 Nature 165 (1997)	
		GLENDENNING, John I., "Effectiveness of Cardenolides as Feeding Deterents to Peromyscus Mice," 18 J. Chem. Ecol. 1559 (1992) (abstract only)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	unassigned
		Filing Date	Sept. 2003
		First Named Inventor	Albert M. FLEISCHNER
		Group Art Unit	
		Examiner Name	
Sheet 1	of	Attorney Docket Number	Nutrimerica

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Blum Ph.D. J, Marshall M.D. P. Randomized Clinical Trial for Healthy Weight-Management A Prospective, Randomized, Double-Blind Study to Test the Efficacy of Trimspa. 2001 August: Bangor, Maine, USA.	
		Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et. al. Herbal ephedra /caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord. 2002 May; 26(5): 593-604.	
		Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord. 1992 Apr; 16(4): 269-277.	
		Boozer CN et al., An herbal supplement containing MaHuang-Guarana for weight loss. Obesity Research Center, St. Luke's-Roosevelt Hospital Center and Department of Medicine, Columbia University College of Physicians and Surgeons, New York, 10025, USA.	
		Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord. 1993 Feb; 17Suppl 1:S41-43.	
		Breum L, et al., Comparison of an ephedrine/caffeine combination and dexfluramine in the treatment of obesity. Int J Obes Relat Metab Disord. 1994 Feb; 18(2): 99-103.	
		A Prospective, Randomized, Double-Blind Study to Evaluate the Effect of Lean System 7 on Body Composition. <a href="http://www.humaneticscorp.com/7keto/7ketoabstracts.html#7ketoabstract16">http://www.humaneticscorp.com/7keto/7ketoabstracts.html#7ketoabstract16</a> (Accessed June 26, 2003).	
		FLANAGAN, Jane, "Bushmen to aid slimmers" (filed 23 Sept 2001) (Telegraph News, publ.)	
		Science & Health Correspondent, "San to benefit from medicinal plant," (Business Day, publ.) (26 March 2003)	
		TULP, Orien Lee et al., "Mineral Content of Edible Hoodia Plant species," 15 FASEB Abstracts 747.3 (March 7, 2001 ?) (abstract only).	
		CARROLL, Rory, "It's green, prickly and sour, but this plant could cure obesity and save an ancient way of life.(4 Jan. 2003) (The Guardian, Johannesburg, publ.)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	unassigned
		Filing Date	Oct 2003
		First Named Inventor	Albert M. FLEISCHNER
		Group Art Unit	
		Examiner Name	
Sheet 1	of	Attorney Docket Number	Nutrimerica

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HASKELL-LUEVANO, Carrie et al., "Discovery of Prototype Peptidomimetic Antagonists ...," 40 J. Med. Chem. 2133 (1997).	
		MITSUHASHI, Hiroshi et al., "Studies on the Constituents of Asclepiadaceae Plants XIII," 4 Steroids 483 (1964)	
		MITSUHASHI, Hiroshi et al., "Studies on the Constituents of Asclepiadaceae Plants XVI," 13 Chem. Pharm. Bull. 1332 (1965)	
		MITSUHASHI, Hiroshi et al., "Studies on the Constituents of Asclepiadaceae Plants XVI," 13 Chem. Pharm. Bull. 1332 (1965) (abstract)	
		MITSUHASHI, Hiroshi et al., "Studies on the Constituents of Asclepiadaceae Plants XXV," 89 Yokugaku Zosshi 1352 (1969)	
		MIWA, Roto et al., "Structural Determinants of the Melanocortin Peptides Required for Activation," 273 J. Pharm. Exper. Therapeutics 367 (1995)	
		NIKAIDO, Hiroo et al., "Components of Boucerosia aucheriana Decne," 18 Chem Pharm Bull 725 (1967)	
		OKI, Michinori et al., "Intramolecular Interaction Between Hydroxyl Group and Carbonyl Moiety...," 41 Bull. Chem. Soc. Jap. 176 (1968).	
		TEMPLETON, J.F. et al., "Progesterone Derivative That Bind to the Digitalis Receptor...," 30 J. Med. Chem. 1502 (1987).	
		YOSHII, Eiichi et al., "Pregn-14-en-20-ones: Facile Preparation...," 20 Chem. Pharm. Bull 1827 (1972) (abstract only).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.